Efficacy of single- and double-hole thoracoscopic lobectomy for treatment of non-small cell lung cancer: a meta-analysis.

objectivesTo compare the effectiveness of single-port and double-port thoracoscopic lobectomy in the treatment of non-small cell lung cancer (NSCLC) using meta-analysis.

methodsWe systematically searched Pubmed, Embase, and Cochrane Library databases to collect literature on single-hole and double-hole thoracoscopic lobectomy for NSCLC with the end date of August 2022. Keywords included "thoracoscopy", "lobectomy", and "non-small cell lung cancer". Two authors independently conducted literature screening, data extraction, and quality evaluation. The quality evaluation tools were the Cochrane bias risk assessment tool and the Newcastle-Ottawa scale. Meta-analysis was performed using RevMan5.3 software. The odds ratio (OR), weighted mean difference (WMD), and 95% Cl were calculated using a fixed-effects model or random-effect model as appropriate.

resultsTen studies were included. These included two randomized controlled studies and eight cohort studies. 1800 sick persons were included in the survey. Among them, 976 sick people underwent single-hole thoracoscopic lobectomy (single-hole group), and 904 had double-hole thoracoscopic lobectomy (double-hole group). The results of the meta-analysis are as follows. The intraoperative bleeding volume [WMD = -13.75, 95% CI (-18.47, -9.03),

conclusionSingle-hole thoracoscopic lobectomy has advantages in reducing intraoperative bleeding volume, alleviating early postoperative pain, and shortening postoperative hospital stay time. Double-hole thoracoscopic lobectomy has advantages in lymph node dissection. Both methods are equally safe and feasible for NSCLC.